Market research
TRXC TransEnterix, Inc
NYSE MKT USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 917M
- P/E ratio
- Not available
- Analyst target
- 1.45
- Dividend yield
- 0.0%
- Beta
- 1.98
Profile
Company facts
- Exchange
- NYSE MKT
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US89366M3007
- Market cap
- 917M
- P/E ratio
- Not available
- Analyst target
- 1.45
- Dividend yield
- 0.0%
- Beta
- 1.98
About
About TransEnterix, Inc
Asensus Surgical, Inc. engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. It digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through a new category of care called Digital Laparoscopy. The company's digital interface enables the use of capabilities, such as augmented intelligence, connectivity, and robotics in laparoscopy, as well as allows to address the current clinical, cognitive, and economic shortcomings in surgery. The company's products include Senhance Surgical System, a multi-port robotic surgery system that allows multiple robotic arms to control instruments and a camera; and SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform. It offers its products directly and through distributors in Europe, the United States, Japan, Taiwan, and internationally. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is based in Morrisville, North Carolina.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TRXC discussion.
5 years, 4 months ago
Asensus Surgical, Inc is currently in a long term uptrend where the price is trading 2.3% above its 200 day moving average.
From a valuation standpoint, the stock is 93.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 92.9.
Asensus Surgical, Inc's total revenue rose by 61.1% to $1M since the same quarter in the previous year.
Its net income has dropped by 0.4% to $-14M since the same quarter in the previous year.
Finally, its free cash flow grew by 11.4% to $-13M since the same quarter in the previous year.
Based on the above factors, Asensus Surgical, Inc gets an overall score of 4/5.